{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:05:30Z","timestamp":1791155130814,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:00:00Z","timestamp":1334620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10787-012-0137-5","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T16:52:12Z","timestamp":1334595132000},"page":"1-9","source":"Crossref","is-referenced-by-count":9,"title":["The kinin system in hypertensive pathophysiology"],"prefix":"10.1007","volume":"21","author":[{"given":"Jagdish N.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,17]]},"reference":[{"key":"137_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0306-3623(98)00225-0","volume":"33","author":"SA Abbas","year":"1999","unstructured":"Abbas SA, Sharma JN, Yusof APM (1999a) Effect of bradykinin and its antagonist on survival time after coronary artery occlusion in rats. Gen Pharmacol 33:243\u2013247","journal-title":"Gen Pharmacol"},{"key":"137_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0162-3109(99)00155-1","volume":"44","author":"SA Abbas","year":"1999","unstructured":"Abbas SA, Sharma JN, Yusof APM (1999b) The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats. Immunopharmacology 44:93\u201398","journal-title":"Immunopharmacology"},{"key":"137_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-8227(98)00104-1","volume":"42","author":"N Abdella","year":"1998","unstructured":"Abdella N, Arouj M Al, Nakhi A Al, Assoussi A Al, Moussa M (1998) Non-insulin-dependent diabetes in Kuwait: prevalence rates and associated risk factors. Diabet Res Clin Pract 42:187\u2013196","journal-title":"Diabet Res Clin Pract"},{"key":"137_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(72)91636-4","volume":"2","author":"A Adetuyibi","year":"1972","unstructured":"Adetuyibi A, Mills IH (1972) Relationship between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man. Lancet 2:203\u2013207","journal-title":"Lancet"},{"key":"137_CR5","first-page":"95","volume":"XX","author":"A Akbar","year":"1998","unstructured":"Akbar A, Sharma JN, Yusof APM (1998) Potentiation of bradykinin-induced responses in the intact and denuded epithelium of guinea pig tracheal preparations. Tissue React XX:95\u2013100","journal-title":"Tissue React"},{"key":"137_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/01.HYP.3.6_Pt_2.II-46","volume":"3","author":"FA Almeida","year":"1981","unstructured":"Almeida FA, Stella RCR, Voos A (1981) Malignant hypertension: a syndrome associated with low plasma kininogen and kinin potentiating factor. Hypertension 3:46\u201350","journal-title":"Hypertension"},{"key":"137_CR7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-4757-0926-1_9","volume":"120A","author":"E Amundsen","year":"1979","unstructured":"Amundsen E, Putter J, Friberger P, Knos M, Larsbraten M, Glaeseaon G (1979) Method for the determination of glandular kallikrein by means of chromogenic tripeptide substrate. Adv Exp Med Biol 120A:83\u201395","journal-title":"Adv Exp Med Biol"},{"key":"137_CR8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.pa.22.040182.000421","volume":"22","author":"M Antonacio","year":"1982","unstructured":"Antonacio M (1982) Angiotensin converting enzyme (ACE) inhibitors. Annu Rev Pharmacol Toxicol 22:57\u201387","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"137_CR9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0003-2697(80)90404-2","volume":"107","author":"TRC Boyde","year":"1980","unstructured":"Boyde TRC, Rahmatullah M (1980) Optimization of conditions for the colorimetric determination of citrulline using monoxime. Anal Biochem 107:424\u2013431","journal-title":"Anal Biochem"},{"key":"137_CR10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJM199711063371906","volume":"337","author":"E Braunwald","year":"1997","unstructured":"Braunwald E (1997) Cardiovascular medicine a turn of the millennium: triumphs, concern and opportunities. New Eng J Med 337:1360\u20131369","journal-title":"New Eng J Med"},{"issue":"Suppl 6","key":"137_CR11","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/00005344-199015061-00009","volume":"15","author":"RM Burch","year":"1990","unstructured":"Burch RM (1990) Kinin signal transduction: role of phosphoinositides and eicosanoids. J Cardiovasc Pharmacol 15(Suppl 6):S44\u2013S46","journal-title":"J Cardiovasc Pharmacol"},{"key":"137_CR12","first-page":"301","volume":"1","author":"J Chao","year":"1998","unstructured":"Chao J, Chao L (1998) Kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Gen Ther Mol Biol 1:301\u2013308","journal-title":"Gen Ther Mol Biol"},{"issue":"3","key":"137_CR13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1113\/expphysiol.2004.028464","volume":"90","author":"J Chao","year":"2005","unstructured":"Chao J, Chao L (2005) Kallikrein\u2013kinin in stroke, cardiovascular and renal disease. Exp Physiol 90(3):291\u2013298","journal-title":"Exp Physiol"},{"issue":"6","key":"137_CR14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1515\/BC.2006.085","volume":"387","author":"J Chao","year":"2006","unstructured":"Chao J, Bledsoe G, Yin H, Chao L (2006) The tissue kallikrein\u2013kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 387(6):665\u2013675","journal-title":"Biol Chem"},{"key":"137_CR15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0735-1097(98)00159-4","volume":"31","author":"CP Cheng","year":"1998","unstructured":"Cheng CP, Onishi K, Ohte N (1998) Functional effects of endogenous bradykinin in congestive heart failure. Am J Coll Cardiol 31:1679\u20131686","journal-title":"Am J Coll Cardiol"},{"key":"137_CR16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0006-2952(71)90292-9","volume":"20","author":"DW Cushman","year":"1971","unstructured":"Cushman DW, Cheung HS (1971) Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20:1637\u20131648","journal-title":"Biochem Pharmacol"},{"key":"137_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.CIR.29.1.66","volume":"29","author":"FM Freitas De","year":"1964","unstructured":"De Freitas FM, Farraco EZ, De Azevedo DF (1964) General circulatory alterations induced by intravenous infusion of synthetic bradykinin in man. Circulation 29:66\u201370","journal-title":"Circulation"},{"issue":"7","key":"137_CR18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2174\/1381612033391315","volume":"9","author":"C Emanuelia","year":"2003","unstructured":"Emanuelia C, Madeddu P (2003) Human tissue kallikrein: a new bullet for the treatment of ischemia. Curr Pharm Des 9(7):589\u2013597","journal-title":"Curr Pharm Des"},{"key":"137_CR19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.pa.32.040192.002455","volume":"32","author":"SG Farmer","year":"1992","unstructured":"Farmer SG, Burch RM (1992) Biochemical and molecular pharmacology of kinin receptors. Annu Rev Pharmacol Toxicol 32:511\u2013536","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"137_CR20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cardfail.2006.06.004","volume":"12","author":"EL Figueiredo","year":"2006","unstructured":"Figueiredo EL, Garcia Leao FV, De Oliveira LV, Moreira Mda C, De souza Figueiredo AF (2006) The amidase activity of human tissue kallikrein is significantly lower in the urine of patients with systolic heart failure. J Cardiovasc Fail 12(8):653\u2013658","journal-title":"J Cardiovasc Fail"},{"key":"137_CR21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1440-1681.1996.tb02780.x","volume":"23","author":"LR Friend","year":"1996","unstructured":"Friend LR, Morris BJ, Gaffney PT, Griffiths LR (1996) Examination of the role of nitric oxide synthase and renal kallikrein as candidate genes for essential hypertension. Exp Pharmacol Physiol 23:564","journal-title":"Exp Pharmacol Physiol"},{"key":"137_CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0003-2697(82)90118-X","volume":"126","author":"LC Green","year":"1982","unstructured":"Green LC, Wagner DA, Glagowski J (1982) Analysis of nitrate, nitrite and15N nitrate in biological fluids. Anal Biochem 126:131\u2013138","journal-title":"Anal Biochem"},{"key":"137_CR23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/diabetes.39.3.299","volume":"39","author":"JN Harvey","year":"1990","unstructured":"Harvey JN, Jaffa AA, Margolius HS (1990) Renal kallikrein abnormalities of diabetic kidney. Diabetes 39:299\u2013303","journal-title":"Diabetes"},{"key":"137_CR24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0002-8703(78)90304-6","volume":"95","author":"K Hashimto","year":"1978","unstructured":"Hashimto K, Hamamoto H, Honda Y (1978) Changes in components of the kinin system and hemodynamics in acute myocardial infarction. Am Heart J 95:619\u2013626","journal-title":"Am Heart J"},{"issue":"1","key":"137_CR25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0022-1759(92)90268-X","volume":"155","author":"JK Horton","year":"1992","unstructured":"Horton JK, Martin RC, Kalinka S, Cushing A, Kitcher JP, O\u2019Sullivan MJ, Baxendale PM (1992) Enzyme immuno assays for the estimation of adenosine 3\u2019, 5\u2019 cyclic monophosphate and guanosine 3\u2019, 5\u2019 cyclic monophosphate in biological fluids. J Immunol Methods 155(1):31\u201340","journal-title":"J Immunol Methods"},{"issue":"5","key":"137_CR26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2337\/diabetes.52.5.1215","volume":"52","author":"AA Jaffa","year":"2003","unstructured":"Jaffa AA, Durazo-Arvizu R, Zheng D, Lackland DT, Srikanth S, Garvey WT, Schmaier AH (2003) Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 52(5):1215\u20131221","journal-title":"Diabetes"},{"key":"137_CR27","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1172\/JCI113254","volume":"80","author":"AA Jaffa","year":"1987","unstructured":"Jaffa AA, Miller DH, Bailey GS, Chao J, Margolius HS (1987) Abnormal regulation of renal kallikrein in experimental diabetes. J Clin Invest 80:1651\u20131659","journal-title":"J Clin Invest"},{"key":"137_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/diabetes.44.2.156","volume":"44","author":"AA Jaffa","year":"1995","unstructured":"Jaffa AA, Rust PF, Mayfield RK (1995) Kinin, a mediator of diabetes induced glomerular hyper filtration. Diabetes 44:156\u2013160","journal-title":"Diabetes"},{"key":"137_CR29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(81)92154-1","volume":"1","author":"FW James","year":"1981","unstructured":"James FW, Donaldson VH (1981) Decreased exercise tolerance and hypertension in severe hereditary deficiency of plasma kininogen. Lancet 1:889","journal-title":"Lancet"},{"key":"137_CR30","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1046\/j.1523-1755.1998.00147.x","volume":"54","author":"MT Kailasam","year":"1998","unstructured":"Kailasam MT, Martinez JA, Cervenka JH, Yen SSC, O\u2019Connor DT, Parmer RJ (1998) Racial differences in renal kallikrein excretion: effect of the ovulatory cycle. Kidney Int 54:1652\u20131658","journal-title":"Kidney Int"},{"key":"137_CR31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0162-3109(97)00029-5","volume":"36","author":"M Katori","year":"1997","unstructured":"Katori M, Majima M (1997) Role of the renal kallikrein\u2013kinin system in the development of hypertension. Immunopharmacology 36:237\u2013242","journal-title":"Immunopharmacology"},{"key":"137_CR32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.94.1.44","volume":"94","author":"MR Kichuck","year":"1996","unstructured":"Kichuck MR, Seyedi N, Zhang X (1996) Regulation of nitric oxide production in human coronary micro vessels and the contribution of local kinin formation. Circulation 94:44\u201351","journal-title":"Circulation"},{"issue":"1","key":"137_CR33","doi-asserted-by":"crossref","first-page":"H418","DOI":"10.1152\/ajpheart.00677.2002","volume":"285","author":"M Koch","year":"2003","unstructured":"Koch M, Wendorf M, Dendorfer A, Wolfrum S, Schulze K, Spillmann F, Schultheiss HP, Tschope C (2003) Cardiac kinin lecel in experimental diabetes mellitus: role of kinases. Am J Physiol Heart Circ Physiol 285(1):H418\u2013H423","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"137_CR34","first-page":"125P","volume":"467","author":"A Koide","year":"1993","unstructured":"Koide A, Zeitlin IJ, Parratt JR (1993) Kinin formation in ischemic heart and aorta of anaesthetized rats. J Physiol 467:125P","journal-title":"J Physiol"},{"key":"137_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","volume":"57","author":"LMF Leeb-Lundberg","year":"2005","unstructured":"Leeb-Lundberg LMF, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005) International Union of Pharmacology. XLV. Classification of the kinin receptor family: From Molecular Mechanisms to Pathophysiological Consequences. Pharmacol Rev 57:27\u201377","journal-title":"Pharmacol Rev"},{"key":"137_CR36","first-page":"25","volume":"47","author":"W Linz","year":"1995","unstructured":"Linz W, Wiemer G, Scholkens BA (1995) Contribution of kinins to the cardiovascular action of converting-enzyme inhibitors. Pharmacol Rev 47:25\u201350","journal-title":"Pharmacol Rev"},{"key":"137_CR37","first-page":"1949","volume":"8","author":"W Linz","year":"1994","unstructured":"Linz W, Wiemer G, Scholkens BA (1994) Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy. Braz J Med Biol Res 8:1949\u20131954","journal-title":"Braz J Med Biol Res"},{"issue":"Suppl 5","key":"137_CR38","first-page":"S96","volume":"11","author":"W Linz","year":"1993","unstructured":"Linz W, Wiemer G, Scholkens BA (1993) Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens 11(Suppl 5):S96\u2013S97","journal-title":"J Hypertens"},{"key":"137_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1476-5381.1966.tb01806.x","volume":"26","author":"W Locherner","year":"1966","unstructured":"Locherner W, Parratt JR (1966) A comparison of the effects of locally and systemically administration of kinin on coronary blood flow and myocardial metabolism. Br J Pharmacol Chemother 26:17\u201326","journal-title":"Br J Pharmacol Chemother"},{"key":"137_CR40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.HYP.32.3.503","volume":"23","author":"P Madeddu","year":"1998","unstructured":"Madeddu P, Milia AF, Salis MB (1998) Renovascular hypertension in bradykinin B2 receptor knockout mice. Hypertension 23:503\u2013509","journal-title":"Hypertension"},{"key":"137_CR41","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/BF02252938","volume":"45","author":"M Majima","year":"1996","unstructured":"Majima M, Nishiyama K, Iguchi Y, Yao K, Ogino M, Ohno T, Sunahara N, Katoh K, Tatemichi N, Takei Y, Katori M (1996) Determination of bradykinin-(1-5) in inflammatory exudates by a new ELISA as a reliable indicator of bradykinin generation. Inflamm Res 45:416\u2013423","journal-title":"Inflamm Res"},{"key":"137_CR42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/01.RES.30.3.358","volume":"30","author":"HS Margolius","year":"1972","unstructured":"Margolius HS, Geller R, DeJong W (1972) Altered urinary kallikrein excretion in rats hypertension. Circ Res 30:358\u2013362","journal-title":"Circ Res"},{"key":"137_CR43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(71)90382-5","volume":"2","author":"HS Margolius","year":"1971","unstructured":"Margolius HS, Geller R, Pisano JJ (1971) Altered urinary kallikrein excretion in human hypertension. Lancet 2:1063\u20131065","journal-title":"Lancet"},{"key":"137_CR44","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/01.RES.35.6.820","volume":"35","author":"HS Margolius","year":"1974","unstructured":"Margolius HS, Horwwitz D, Pisano JJ (1974) Urinary kallikrein excretion in hypertensive man: relationship to sodium intake and sodium-retaining steroids. Circ Res 35:820\u2013825","journal-title":"Circ Res"},{"key":"137_CR45","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2337\/diabetes.54.5.1573","volume":"54","author":"D Montanari","year":"2005","unstructured":"Montanari D, Yin H, Dobrzynski E, Agata J, Yoshida H, Chao J, Chao L (2005) Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 54:1573\u20131580","journal-title":"Diabetes"},{"issue":"1","key":"137_CR46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","volume":"99","author":"ME Moreau","year":"2005","unstructured":"Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A (2005) The kallikrein\u2013kinin system: current and future pharmacological targets. J Pharmacol Sci 99(1):6\u201338","journal-title":"J Pharmacol Sci"},{"key":"137_CR47","first-page":"125","volume":"49","author":"JC McGiff","year":"1975","unstructured":"McGiff JC, Itskovitz HD, Terrango NA (1975) The action of bradykinin and eledoicin in the canine isolated kidney: a relationship to prostaglandins. Clin Sci Mol Med 49:125\u2013131","journal-title":"Clin Sci Mol Med"},{"key":"137_CR48","first-page":"175","volume":"23","author":"IH Mills","year":"1982","unstructured":"Mills IH (1982) The renal kallikrein\u2013kinin system and sodium excretion. Q J Exp Physiol 23:175\u2013180","journal-title":"Q J Exp Physiol"},{"key":"137_CR49","first-page":"73","volume":"7","author":"SSJ Mohsin","year":"1992","unstructured":"Mohsin SSJ, Majima M, Katori M, Sharma JN (1992) Important suppressive roles of the kallikrein\u2013kinin system during the developmental stage of hypertension in spontaneously hypertensive rats. Asia Pacific J Pharmacol 7:73\u201382","journal-title":"Asia Pacific J Pharmacol"},{"key":"137_CR50","first-page":"H1209","volume":"265","author":"HL Nolly","year":"1981","unstructured":"Nolly HL, Britos J (1981) Kinin-forming enzyme in rat cardiac tissue. Am J Physiol 265:H1209\u2013H1214","journal-title":"Am J Physiol"},{"key":"137_CR51","first-page":"H1209","volume":"265","author":"HL Nolly","year":"1993","unstructured":"Nolly HL, Carretero OA, Sclicli AG (1993) Kallikrein release by vascular tissue. Am J Physiol 265:H1209\u2013H1214","journal-title":"Am J Physiol"},{"key":"137_CR52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0162-3109(96)00078-1","volume":"33","author":"JK Platts","year":"1996","unstructured":"Platts JK, Meadows P, Harvey JN (1996) The relationship between urinary kallikrein and glomerular filtration rate (GFR) in type-1 diabetes: studies with lithium. Immunopharmacology 33:351\u2013353","journal-title":"Immunopharmacology"},{"key":"137_CR53","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/01.HYP.17.2.242","volume":"17","author":"M Pravence","year":"1991","unstructured":"Pravence M, Ken V, Kunes J (1991) Cosegregation of blood pressure with kallikrein gene family polymorphism. Hypertension 17:242\u2013246","journal-title":"Hypertension"},{"issue":"Suppl 3","key":"137_CR54","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1097\/00005344-198406002-00015","volume":"6","author":"D Regoli","year":"1984","unstructured":"Regoli D (1984) Neurohumoral regulation of precapillary vessels: the kallikrein\u2013kinin system. J Cardiovasc Pharmacol 6(Suppl 3):S401\u2013S412","journal-title":"J Cardiovasc Pharmacol"},{"key":"137_CR55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2133.2005.06427.x","volume":"152","author":"TB Rosatelli","year":"2005","unstructured":"Rosatelli TB, Roselino AM, Dellalibera-Joviliano R, Reis ML, Donadi EA (2005) Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in Pemphigus foliaceus (fogo selvagem). Br J Dermatol 152:650\u2013657","journal-title":"Br J Dermatol"},{"key":"137_CR56","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.76.3.434","volume":"76","author":"LE Rubin","year":"1995","unstructured":"Rubin LE, Levi R (1995) Protective role of bradykinin in cardiac anaphylaxis. Circ Res 76:434\u2013440","journal-title":"Circ Res"},{"key":"137_CR57","first-page":"1823","volume":"43","author":"VB Schini","year":"1990","unstructured":"Schini VB, Boulanger C, Regoli D, Vonhoutte PM (1990) Bradykinin stimulates the production of cyclicGMP via activation of B2 receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 43:1823\u20131827","journal-title":"J Pharmacol Exp Ther"},{"key":"137_CR58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0162-3109(96)00061-6","volume":"33","author":"BA Scholkens","year":"1996","unstructured":"Scholkens BA (1996) Kinins in the cardiovascular system. Immunopharmacology 33:209\u2013217","journal-title":"Immunopharmacology"},{"key":"137_CR59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.arcmed.2005.08.001","volume":"37","author":"JN Sharma","year":"2006","unstructured":"Sharma JN (2006) The tissue kallikrein\u2013kininogem\u2013kinin pathways: role in cardiovascular system. Arch Med Res 37:299\u2013306","journal-title":"Arch Med Res"},{"issue":"5","key":"137_CR60","first-page":"591","volume":"12","author":"JN Sharma","year":"2005","unstructured":"Sharma JN (2005) The kallikrein\u2013kinin system: from mediator of inflammation to modulator of cardioprotection. Immunopharmacology 12(5):591\u2013596","journal-title":"Immunopharmacology"},{"key":"137_CR61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0091270003258171","volume":"43","author":"JN Sharma","year":"2003","unstructured":"Sharma JN (2003) Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol 43:1187\u20131195","journal-title":"J Clin Pharmacol"},{"key":"137_CR62","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0306-3623(93)90302-E","volume":"24","author":"JN Sharma","year":"1993","unstructured":"Sharma JN (1993) Therapeutic prospects of bradykinin antagonists. Gen Pharmacol 24:267\u2013274","journal-title":"Gen Pharmacol"},{"issue":"III","key":"137_CR63","first-page":"343","volume":"38","author":"JN Sharma","year":"1992","unstructured":"Sharma JN (1992) Involvement of the kinin-forming system in physiopathology of rheumatoid inflammation. Agents Actions 38(III):343\u2013361","journal-title":"Agents Actions"},{"issue":"4","key":"137_CR64","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0306-3623(90)90697-K","volume":"21","author":"JN Sharma","year":"1990","unstructured":"Sharma JN (1990) Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors? Gen Pharmacol 21(4):451\u2013457","journal-title":"Gen Pharmacol"},{"key":"137_CR65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4615-9543-4_28","volume":"247A","author":"JN Sharma","year":"1989","unstructured":"Sharma JN (1989) Contribution of kinin system to the antihypertensive action of angiotensin converting enzyme inhibitors. Adv Exp Med Biol 247A:197\u2013205","journal-title":"Adv Exp Med Biol"},{"key":"137_CR66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2005.03.005","volume":"52","author":"JN Sharma","year":"2005","unstructured":"Sharma JN, Abbas SA (2005) Bradykinin antagonist abolishes beneficial effect of captopril on duration of survival after acute coronary artery ligation in hypertensive rats. Pharmacol Res 52:211\u2013215","journal-title":"Pharmacol Res"},{"key":"137_CR67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000139305","volume":"50","author":"JN Sharma","year":"1995","unstructured":"Sharma JN, Amrah SS, Noor AR (1995) Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitor aprotinin in spontaneously hypertensive rats. Pharmacology 50:363\u2013369","journal-title":"Pharmacology"},{"key":"137_CR68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0940-2993(11)80053-9","volume":"46","author":"JN Sharma","year":"1994","unstructured":"Sharma JN, Buchanan WW (1994) Pathogenic responses of bradykinin system in chronic inflammatory rheumatoid disease. Exp Toxicol Pathol 46:421\u2013433","journal-title":"Exp Toxicol Pathol"},{"key":"137_CR69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1139\/y84-036","volume":"62","author":"JN Sharma","year":"1984","unstructured":"Sharma JN, Fernandez PG, Laher I (1984) Differential sensitivity of Dahl salt-sensitive and salt-resistant rats to the hypotensive action of acute nifedipine administration. Can J Physiol Pharmacol 62:241\u2013243","journal-title":"Can J Physiol Pharmacol"},{"key":"137_CR70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00004872-198310000-00009","volume":"1","author":"JN Sharma","year":"1983","unstructured":"Sharma JN, Fernandez PG, Kim BK (1983) Cardiac regression and blood pressure control in Dahl rats treated with enalapril maleate (MK 421), an angiotensin converting enzyme inhibitor. J Hypertens 1:251\u2013256","journal-title":"J Hypertens"},{"key":"137_CR71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0232-1513(11)80241-0","volume":"38","author":"JN Sharma","year":"1990","unstructured":"Sharma JN, Mohsin SSJ (1990) The role of chemical mediators in pathogenesis of inflammation with emphasis on the kinin system. Exp Pathol 38:73\u201396","journal-title":"Exp Pathol"},{"key":"137_CR72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1185\/03007990212500093","volume":"18","author":"JN Sharma","year":"2002","unstructured":"Sharma JN (2002) Cardiovascular properties of the kallikrein\u2013kinin system. Curr Med Res Opin 18:10\u201317","journal-title":"Curr Med Res Opin"},{"key":"137_CR73","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000056171","volume":"64","author":"JN Sharma","year":"2002","unstructured":"Sharma JN, Uma K (2002) Effect of captopril on urinary kallikrein, blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats. Pharmacology 64:196\u2013200","journal-title":"Pharmacology"},{"key":"137_CR74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0162-3109(99)00070-3","volume":"43","author":"JN Sharma","year":"1999","unstructured":"Sharma JN, Uma K, Yusof APM (1999) Altered cardiac tissue and plasma kininogen levels in hypertensive and diabetic rats. Immunopharmacology 43:129\u2013132","journal-title":"Immunopharmacology"},{"key":"137_CR75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0167-5273(97)00329-X","volume":"63","author":"JN Sharma","year":"1998","unstructured":"Sharma JN, Uma K, Yusof APM (1998) Left ventricular hypertrophy and its relation to cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 63:229\u2013235","journal-title":"Int J Cardiol"},{"key":"137_CR76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0162-3109(96)00104-X","volume":"33","author":"JN Sharma","year":"1996","unstructured":"Sharma JN, Uma K (1996) Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacology 33:341\u2013343","journal-title":"Immunopharmacology"},{"key":"137_CR77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0306-3623(95)00028-3","volume":"27","author":"JN Sharma","year":"1996","unstructured":"Sharma JN, Uma K, Noor AR (1996) Blood pressure regulation by the kallikrein\u2013kinin system. Gen Pharmacol 27:55\u201363","journal-title":"Gen Pharmacol"},{"key":"137_CR78","first-page":"125","volume":"1","author":"JN Sharma","year":"1981","unstructured":"Sharma JN, Zeitlin IJ (1981) Altered plasma kininogen in clinical hypertension. Lancet 1:125\u2013126","journal-title":"Lancet"},{"key":"137_CR79","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.2042-7158.1977.tb11324.x","volume":"29","author":"JN Sharma","year":"1977","unstructured":"Sharma JN, Zeitlin IJ (1977) Indomethacin in low concentration potentiates the actions of some spasmogens on the isolated estrous rat uterus. J Pharm Pharmacol 29:316\u2013317","journal-title":"J Pharm Pharmacol"},{"key":"137_CR80","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1111\/j.1365-2125.1982.tb02063.x","volume":"14","author":"K Silberbauer","year":"1982","unstructured":"Silberbauer K, Stanek B, Temple H (1982) Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 14:87S\u201393S","journal-title":"Br J Clin Pharmacol"},{"key":"137_CR81","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0162-3109(99)00138-1","volume":"44","author":"C Smith","year":"1999","unstructured":"Smith C, Campbell S, Albano J (1999) Urinary kallikrein excretion in normotensive and hypertensive pregnancies: 8\u00a0years later. Immunopharmacol 44:177\u2013182","journal-title":"Immunopharmacol"},{"issue":"1","key":"137_CR82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.mnh.0000199009.56799.2b","volume":"15","author":"F Spillmann","year":"2006","unstructured":"Spillmann F, Van Linthout S, Schultheiss HP, Tschope C (2006) Cardioprotective mechanisms of the kallikrein\u2013kinin system in diabetic cardiopathy. Curr Opin Nephrol Hypertens 15(1):22\u201329","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"26","key":"137_CR83","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2174\/138161206778194051","volume":"12","author":"JB Su","year":"2006","unstructured":"Su JB (2006) Kinins and cardiovascular diseases. Curr Pharm Des 12(26):3423\u20133435","journal-title":"Curr Pharm Des"},{"issue":"3","key":"137_CR84","doi-asserted-by":"crossref","first-page":"F483","DOI":"10.1152\/ajprenal.00165.2004","volume":"288","author":"Y Tan","year":"2005","unstructured":"Tan Y, Wang B, Keum JS, Jaffa AA (2005) Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 288(3):F483\u2013F492","journal-title":"Am J Physiol Renal Physiol"},{"key":"137_CR85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0162-3109(96)00094-X","volume":"33","author":"G Tschope","year":"1996","unstructured":"Tschope G, Gavriluk V, Reinecke A (1996) Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology 33:344\u2013348","journal-title":"Immunopharmacology"},{"key":"137_CR86","first-page":"H2333","volume":"277","author":"C Tshope","year":"1999","unstructured":"Tshope C, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T (1999) Functional, biochemical, and molecular investigations of renal kallikrein\u2013kinin system in diabetic rats. Am J Physiol 277:H2333\u2013H2340","journal-title":"Am J Physiol"},{"key":"137_CR87","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1476-5381.1994.tb17120.x","volume":"107","author":"A Vegh","year":"1994","unstructured":"Vegh A, Rapp JG, Parratt JR (1994) Attenuation of the antiarrhythmic effects of ischemia preconditioning by blocked of bradykinin B2 receptors. Br J Pharmacol 107:1167\u20131172","journal-title":"Br J Pharmacol"},{"key":"137_CR88","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1476-5381.1991.tb12424.x","volume":"104","author":"A Vegh","year":"1991","unstructured":"Vegh A, Szekeres L, Parratt RJ (1991) Local intracoronary infusions of bradykinin profoundly reduce the severity of ischemia-induced arrhythmia in anaesthetized dogs. Br J Pharmacol 104:294\u2013295","journal-title":"Br J Pharmacol"},{"key":"137_CR89","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/0006-2952(94)90549-5","volume":"47","author":"MAR Vieira","year":"1994","unstructured":"Vieira MAR, Moreira FM, Maack T (1994) Conversion of T-kinin to bradykinin by the rat kidney. Biochem Pharmacol 47:1693\u20131699","journal-title":"Biochem Pharmacol"},{"key":"137_CR90","first-page":"681","volume":"270","author":"TM Walls","year":"1994","unstructured":"Walls TM, Sheehy R, Hartman JC (1994) Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270:681\u2013689","journal-title":"J Pharmacol Exp Ther"},{"key":"137_CR91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/01.HYP.23.2.236","volume":"23","author":"C Wang","year":"1994","unstructured":"Wang C, Chao L, Chao J (1994) Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23:236\u2013243","journal-title":"Hypertension"},{"key":"137_CR92","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1152\/ajplegacy.1964.206.4.714","volume":"206","author":"ME Webster","year":"1964","unstructured":"Webster ME, Gilmore JP (1964) Influence of kallidin-10 on renal function. Am J Physiol 206:714\u2013718","journal-title":"Am J Physiol"},{"key":"137_CR93","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00004872-198911000-00003","volume":"7","author":"C Woolly-Miller","year":"1989","unstructured":"Woolly-Miller C, Chao J, Chao L (1989) Restriction fragment length polymorphism\u2019s mapped in spontaneously hypertensive rats using kallikrein probs. J Hypertens 7:865\u2013871","journal-title":"J Hypertens"},{"key":"137_CR94","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0008-6363(96)88637-8","volume":"29","author":"P Zhu","year":"1995","unstructured":"Zhu P, Zugga CE, Simper D (1995) Bradykinin improves post-ischemic recovery in that rat heart: role of high energy phosphate, nitric oxide and prostacycline. Cardiovacs Res 29:658\u2013663","journal-title":"Cardiovacs Res"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-012-0137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-012-0137-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-012-0137-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T10:55:22Z","timestamp":1561632922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-012-0137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,17]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1007\/s10787-012-0137-5","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,17]]}}}